ARLINGTON, Mass, July 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of ...
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today provided an update on the development plan for KPI-121 0.25%, which if approved could be the first FDA-approved product ...
ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
ARLINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results